Health Condition 1: J454- Moderate persistent asthma
Conditions
Interventions
None listed
Sponsors
Ayurvedic and Unani Tibbia College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient has asthma with severity ranging from Intermittent asthma to Moderate Persistent asthma, according to the NAEPP 2020 Guidelines. 2. FEV1 more than 60%. 3. Chronicity less than 10 years 4. Patient presenting with features of Tamaka shwasa as in ayurvedic classical textbooks
Exclusion criteria
Exclusion criteria: 1.Patients on prolonged (more than 6 weeks) medication with corticosteroids, bronchodilators, mast cells stabilizers, antidepressants, anticholinergics, or any other drugs that may have an influence on the outcome of the study. 2.Patients who have a past history of Atrial fibrillation, Acute Coronary Syndrome, Myocardial Infraction, stroke or severe Arrhythmia in last 6 months 3.Patient having systemic illness necessitating long term drug treatment like TB, carcinoma, endocrine disorders, concurrent major liver or renal disorders, psychological disorders, neurological disorders like epilepsy, meningitis, stroke etc. 4.Patients who have completed participation in any other clinical trial during the past 6 months 5.Patient having pulmonary diseases other than asthma 6.Patient with Diabetes mellitus (FBS more than 126 mg/dl) 7.Patient with poorly controlled Hypertension (Systolic more than 140mm Hg and Diastolic more than 90 mm of Hg) 8.Patient having SPO2 less than 90% 9.Emergency patients requiring O2 inhalation 10.Hypersensitivity to any of the content of the trial drug 11.Pregnant and lactating women 12.Smoker or alcoholic or drug abusers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the changes in frequency and severity of asthma symptoms as assessed by grading of clinical symptoms, Asthma control questionnaire. Proportion of participants having 50% relief in the grading of clinical symptoms will be considered as improvementTimepoint: Day 1, 91 | — |
Secondary
| Measure | Time frame |
|---|---|
| Measure changes in pulmonary function parameters such as FEV1, FVC, PEFR, before and after treatment. Evaluate improvement in quality of life using Asthma quality of life questionnaire Evaluate the reduction in serum IgE level and Absolute eosinophil count.Timepoint: Day 1, 91 | — |
Countries
India
Contacts
Public ContactDr Sujata Yadav
Ayurvedic and Unani Tibbia College and Hospital
Outcome results
None listed